Education
About Us
Working with TipRanks
Follow Us
Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
AGN Stock Chart & Stats
AU$0.26
<AU$0.01(0.81%)
At close: 4:00 PM EST
AU$0.26
<AU$0.01(0.81%)
Day’s Range― - ―
52-Week RangeAU$0.19 - AU$0.89
Previous CloseN/A
Volume9.34K
Average Volume (3M)511.75K
Market Cap
AU$33.40M
Enterprise ValueAU$22.84M
Total Cash (Recent Filing)AU$10.56M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.65
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,456,710
10 Day Avg. Volume288,263
30 Day Avg. Volume511,745
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)13.39
Price to Sales (P/S)30.16
P/FCF Ratio-16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.64Price Target Upside146.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Top-line GrowthConsistent year-over-year revenue growth shows the company is advancing its product candidates and generating increasing commercial or milestone receipts. A rising top line provides a firmer base for future scale and supports longer-term R&D investment if cost control follows.
Conservative LeverageZero reported debt materially reduces refinancing and interest burden risks common in biotech. This structural strength gives management flexibility to fund trials and absorb setbacks without immediate debt servicing pressure, improving resilience over the next several quarters.
Improving Cash Flow TrendAn improving free cash flow trajectory, even from negative levels, indicates operational progress or better cash management and suggests the firm may need progressively less external funding if the trend continues. Trend improvement supports longer-term operational sustainability.
Bears Say
Deep Negative ProfitabilityExtremely negative margins reflect costs far exceeding current revenue, signaling the core business is not profitable and is highly reliant on external financing or major operational change. This structural unprofitability threatens runway and strategic optionality absent decisive improvement.
Sustained Cash BurnPersistent negative operating and free cash flow indicates ongoing funding needs to support R&D and operations. Over a multi-quarter horizon this raises the probability of dilutive financings and constrains long-term planning, increasing execution risk for clinical programs.
Eroding Equity BaseA halving of equity in a year highlights capital consumption from losses and reduces the balance-sheet buffer against setbacks. A weakened equity base makes further equity raises likelier and can dilute existing holders, limiting financial flexibility and strategic options over the medium term.
Argenica Therapeutics Ltd News
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.19 and its highest was AU$0.89 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Argenica Therapeutics Ltd’s market cap is AU$33.40M.
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Currently, no data Available
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Undervalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,456,710 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenica Therapeutics Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.64 (146.15% Upside)
AU$0.64 (146.15% Upside)
Blogger Sentiment
Bullish
AU:AGN Sentiment 94%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.48%
12-Months-Change
Fundamentals
Return on Equity
-67.68%
Trailing 12-Months
Asset Growth
-32.60%
Trailing 12-Months
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.
AGN Stock 12 Month Forecast
Average Price Target
AU$0.64
▲(146.15% Upside)
Technical Analysis
Alterity Therapeutics
―
Race Oncology Ltd.
―
Nanollose Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Options Prices
Currently, No data available
---